Indian Drug Makers Succeed In Reducing R&D Costs
This article was originally published in PharmAsia News
Executive Summary
Six of India's pharmaceutical makers have been successful in trimming research costs recently by separating new-drug development operations from their generic and domestic operations. Lupin, Sun Pharmaceuticals and Wockhardt reduced their research costs by 5.8 percent of operating income in the first quarter of this year. Dr Reddy's, Nicholas Piramal and Ranbaxy Laboratories also have been able to reduce their research costs compared with the same quarter of last year. (Click here for more